22 research outputs found
Application of family-based tests of association for rare variants to pathways
Pathway analysis approaches for sequence data typically either operate in a single stage (all variants within all genes in the pathway are combined into a single, very large set of variants that can then be analyzed using standard gene-based test statistics) or in 2-stages (gene-based p values are computed for all genes in the pathway, and then the gene-based p values are combined into a single pathway p value). To date, little consideration has been given to the performance of gene-based tests (typically designed for a smaller number of single-nucleotide variants [SNVs]) when the number of SNVs in the gene or in the pathway is very large and the genotypes come from sequence data organized in large pedigrees. We consider recently proposed gene-based tests for rare variants from complex pedigrees that test for association between a large set of SNVs and a qualitative phenotype of interest (1-stage analyses) as well as 2-stage approaches. We find that many of these methods show inflated type I errors when the number of SNVs in the gene or the pathway is large (\u3e200 SNVs) and when using standard approaches to estimate the genotype covariance matrix. Alternative methods are needed when testing very large sets of SNVs in 1-stage approaches
Evaluation of the power and type I error of recently proposed family-based tests of association for rare variants
Evaluation of the Power and Type 1 Error of Recently Proposed Family-based Tests of Assocations for Rare Variants
Until very recently, few methods existed to analyze rare-variant association with binary phenotypes in complex pedigrees. We consider a set of recently proposed methods applied to the simulated and real hypertension phenotype as part of the Genetic Analysis Workshop 18. Minimal power of the methods is observed for genes containing variants with weak effects on the phenotype. Application of the methods to the real hypertension phenotype yielded no genes meeting a strict Bonferroni cutoff of significance. Some prior literature connects 3 of the 5 most associated genes (p \u3c1 × 10−4) to hypertension or related phenotypes. Further methodological development is needed to extend these methods to handle covariates, and to explore more powerful test alternatives
Application of Family-based Tests of Association for Rare Variants to Pathways
Pathway analysis approaches for sequence data typically either operate in a single stage (all variants within all genes in the pathway are combined into a single, very large set of variants that can then be analyzed using standard “gene-based” test statistics) or in 2-stages (gene-based p values are computed for all genes in the pathway, and then the gene-based p values are combined into a single pathway p value). To date, little consideration has been given to the performance of gene-based tests (typically designed for a smaller number of single-nucleotide variants [SNVs]) when the number of SNVs in the gene or in the pathway is very large and the genotypes come from sequence data organized in large pedigrees. We consider recently proposed gene-based tests for rare variants from complex pedigrees that test for association between a large set of SNVs and a qualitative phenotype of interest (1-stage analyses) as well as 2-stage approaches. We find that many of these methods show inflated type I errors when the number of SNVs in the gene or the pathway is large (\u3e200 SNVs) and when using standard approaches to estimate the genotype covariance matrix. Alternative methods are needed when testing very large sets of SNVs in 1-stage approaches
General Approaches for Combining Multiple Rare Variant Associate Tests Provide Improved Power Across a Wider Range of Genetic Architecture
In the wake of the widespread availability of genome sequencing data made possible by way of nextgeneration technologies, a flood of gene‐based rare variant tests have been proposed. Most methods claim superior power against particular genetic architectures. However, an important practical issue remains for the applied researcher—namely, which test should be used for a particular association study which may consider multiple genes and/or multiple phenotypes. Recently, tests have been proposed which combine individual tests to minimize power loss while improving the robustness to a wide range of genetic architectures. In our analysis, we propose an expansion of these approaches, by providing a general method that works for combining an arbitrarily large number of any gene‐based rare variant test—a flexibility typically not available in other combined testing methods. We provide a theoretical framework for evaluating our combined test to provide direct insights into the relationship between test‐test correlation, test power and the combined test power relative to individual testing approaches and other combined testing approaches. We demonstrate that our flexible combined testing method can provide improved power and robustness against a wide range of genetic architectures. We further demonstrate the performance of our combined test on simulated genotypes, as well as on a dataset of real genotypes with simulated phenotypes. We support the increased use of flexible combined tests in practice to maximize robustness of rare‐variant testing strategies against a wide‐range of genetic architectures
General Approach for Combining Diverse Rare Variant Association Tests Provides Improved Robustness Across a Wider Range of Genetic Architectures
The widespread availability of genome sequencing data made possible by way of next-generation technologies has yielded a flood of different gene-based rare variant association tests. Most of these tests have been published because they have superior power for particular genetic architectures. However, for applied researchers it is challenging to know which test to choose in practice when little is known a priori about genetic architecture. Recently, tests have been proposed which combine two particular individual tests (one burden and one variance components) to minimize power loss while improving robustness to a wider range of genetic architectures. In our analysis we propose an expansion of these approaches, yielding a general method that works for combining any number of individual tests. We demonstrate that running multiple different tests on the same dataset and using a Bonferroni correction for multiple testing is never better than combining tests using our general method. We also find that using a test statistic that is highly robust to the inclusion of non-causal variants (Joint-infinity) together with a previously published combined test (SKAT-O) provides improved robustness to a wide range of genetic architectures and should be considered for use in practice. Software for this approach is supplied. We support the increased use of combined tests in practice-- as well as further exploration of novel combined testing approaches using the general framework provided here--to maximize robustness of rare-variant testing strategies against a wide range of genetic architectures
The James Webb Space Telescope Mission
Twenty-six years ago a small committee report, building on earlier studies,
expounded a compelling and poetic vision for the future of astronomy, calling
for an infrared-optimized space telescope with an aperture of at least .
With the support of their governments in the US, Europe, and Canada, 20,000
people realized that vision as the James Webb Space Telescope. A
generation of astronomers will celebrate their accomplishments for the life of
the mission, potentially as long as 20 years, and beyond. This report and the
scientific discoveries that follow are extended thank-you notes to the 20,000
team members. The telescope is working perfectly, with much better image
quality than expected. In this and accompanying papers, we give a brief
history, describe the observatory, outline its objectives and current observing
program, and discuss the inventions and people who made it possible. We cite
detailed reports on the design and the measured performance on orbit.Comment: Accepted by PASP for the special issue on The James Webb Space
Telescope Overview, 29 pages, 4 figure
Frequentist and Bayesian Modeling in the Presence of Unmeasured Confounding
Biostatistical studies of medical data are extremely important in distinguishing relationships between drugs or treatments and the patient's medical response. These studies generally use data from large health care databases, which provide immense amounts of information while allowing the researcher to analyze long-term effects that may not be shown in a typical randomized controlled trial. However, when using large databases, one must be particularly aware of the effect of unmeasured confounding on statistical models. Confounding arises when factors unrelated to the particular study have a hidden effect on observed health outcomes. Bayesian statistics provides a mechanism for model fitting which synthesizes the data with prior information about bias, allowing the researcher to control confounding through the inclusion of additional variables from independent datasets. In this thesis I will provide a background of the proposed method as well its application to two independent analyses: predictors of low birth weight babies and predictors of parental separation anxiety